{
  "id": "mhgap#screening_cues_c7c00da5",
  "content": "generic antidepressants varies from region to region continuous availability, costs).\nthroughout the world ranging between 3% and 9% y Explain rationale for prescribing and provide written\nof minimum wage (131). and verbal information on benefits and harms,\ny For the treatment of depressive disorder, the WHO side-effects, drug interactions, the importance\nEML (13) includes: of taking medicines as prescribed and the likely\n– TCA: amitriptyline; time to improvement in symptoms.\n– SSRI: fluoxetine (therapeutic alternatives: y Regularly review the effectiveness of the medicine\ncitalopram, escitalopram, fluvoxamine, and side-effects with the person during the first\nparoxetine and sertraline). three months of treatment and every three months\nafterwards. For adults who experience side-effects\ny The Interagency health kit 2017 includes fluoxetine\nafter starting medicine, consider closer monitoring\n(133).\nof their symptoms, reducing the dose of the\ny Specific types of antidepressants selected should\nmedicine or stopping the medicine gradually and\ncarefully consider factors such as demographic\noffering alternative interventions.\nDEP2. How long should treatment with antidepressants continue in\nadults with depressive episode/disorder?\nRecommendation (update): In adults with moderate-to-severe depression who have benefited from initial\nantidepressant treatment, continuation of the antidepressant treatment\nshould be considered for at least six months after remission. Treatment",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues generic antidepressants varies from region to region continuous availability, costs).\nthroughout the world ranging between 3% and 9% y Explain rationale for prescribing and provide written\nof minimum wage (131). and verbal information on benefits and harms,\ny For the treatment of depressive disorder, the WHO side-effects, drug interactions, the importance\nEML (13) includes: of taking medicines as prescribed and the likely\n– TCA: amitriptyline; time to improvement in symptoms.\n– SSRI: fluoxetine (therapeutic alternatives: y Regularly review the effectiveness of the medicine\ncitalopram, escitalopram, fluvoxamine, and side-effects with the person during the first\nparoxetine and sertraline). three months of treatment and every three months\nafterwards. For adults who experience side-effects\ny The Interagency health kit 2017 includes fluoxetine\nafter starting medicine, consider closer monitoring\n(133).\nof their symptoms, reducing the dose of the\ny Specific types of antidepressants selected should\nmedicine or stopping the medicine gradually and\ncarefully consider factors such as demographic\noffering alternative interventions.\nDEP2. How long should treatment with antidepressants continue in\nadults with depressive episode/disorder?\nRecommendation (update): In adults with moderate-to-severe depression who have benefited from initial\nantidepressant treatment, continuation of the antidepressant treatment\nshould be considered for at least six months after remission. Treatment Generic antidepressants varies from region to region continuous availability, costs). throughout the world ranging between 3% and 9% y explain rationale for prescribing and provide written\nof minimum wage (131)."
}